A citation-based method for searching scientific literature

Hsien-Yuan Lane, Ching-Hua Lin, Yu-Jhen Huang, Chun-Hui Liao, Yue-Cune Chang, Guochuan E Tsai. Int J Neuropsychopharmacol 2010
Times Cited: 125







List of co-cited articles
1523 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
209
67

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
51

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
505
46

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Hsien-Yuan Lane, Yi-Ching Liu, Chieh-Liang Huang, Yue-Cune Chang, Chun-Hui Liau, Cheng-Hwang Perng, Guochuan E Tsai. Biol Psychiatry 2008
116
44


D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
267
39

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Hsien-Yuan Lane, Chieh-Liang Huang, Po-Lun Wu, Yi-Ching Liu, Yue-Cune Chang, Pao-Yen Lin, Po-Wei Chen, Guochuan Tsai. Biol Psychiatry 2006
117
38

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
158
33

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
356
31

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
30

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
30

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
293
29

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Mark Weiser, Uriel Heresco-Levy, Michael Davidson, Daniel C Javitt, Nomi Werbeloff, Ari A Gershon, Yehuda Abramovich, Daniela Amital, Adiel Doron, Shai Konas,[...]. J Clin Psychiatry 2012
67
40

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javitt. Biol Psychiatry 2004
173
26

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
134
25

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
138
25


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
23

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, A Horowitz, D Kelly. Br J Psychiatry 1996
198
23

D-alanine added to antipsychotics for the treatment of schizophrenia.
Guochuan E Tsai, Pinchen Yang, Yue-Cune Chang, Mian-Yoon Chong. Biol Psychiatry 2006
135
22

D-serine added to clozapine for the treatment of schizophrenia.
G E Tsai, P Yang, L C Chung, I C Tsai, C W Tsai, J T Coyle. Am J Psychiatry 1999
165
21

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
Daniela Alberati, Jean-Luc Moreau, Judith Lengyel, Nicole Hauser, Roland Mory, Edilio Borroni, Emmanuel Pinard, Frederic Knoflach, Götz Schlotterbeck, Dominik Hainzl,[...]. Neuropharmacology 2012
90
23

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine.
Kenji Hashimoto, Yuko Fujita, Mao Horio, Shinsui Kunitachi, Masaomi Iyo, Dana Ferraris, Takashi Tsukamoto. Biol Psychiatry 2009
104
19

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
19

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.
Thomas Papouin, Laurent Ladépêche, Jérôme Ruel, Silvia Sacchi, Marilyne Labasque, Marwa Hanini, Laurent Groc, Loredano Pollegioni, Jean-Pierre Mothet, Stéphane H R Oliet. Cell 2012
447
18



Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Kenji Hashimoto, Takeshi Fukushima, Eiji Shimizu, Naoya Komatsu, Hiroyuki Watanabe, Naoyuki Shinoda, Michiko Nakazato, Chikara Kumakiri, Shin-ichi Okada, Hisanori Hasegawa,[...]. Arch Gen Psychiatry 2003
381
17

Glutamate receptor dysfunction and schizophrenia.
J W Olney, N B Farber. Arch Gen Psychiatry 1995
17

Amelioration of negative symptoms in schizophrenia by glycine.
D C Javitt, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer. Am J Psychiatry 1994
286
17

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
D C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle. Arch Gen Psychiatry 1999
308
16

Adjunctive high-dose glycine in the treatment of schizophrenia.
D C Javitt, G Silipo, A Cienfuegos, A M Shelley, N Bark, M Park, J P Lindenmayer, R Suckow, S R Zukin. Int J Neuropsychopharmacol 2001
122
16

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Chih-Chia Huang, I-Hua Wei, Chieh-Liang Huang, Kuang-Ti Chen, Mang-Hung Tsai, Priscilla Tsai, Rene Tun, Kuo-Hao Huang, Yue-Cune Chang, Hsien-Yuan Lane,[...]. Biol Psychiatry 2013
90
16


Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Annick Coste, Christophe Lanneau, Christophe Desvignes, Martine Poncelet, Michel Heaulme, Vincent Santucci, Michel Decobert,[...]. Neuropsychopharmacology 2005
178
14

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green. Schizophr Res 2008
94
14

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Michael Berk, David Copolov, Olivia Dean, Kristy Lu, Sue Jeavons, Ian Schapkaitz, Murray Anderson-Hunt, Fiona Judd, Fiona Katz, Paul Katz,[...]. Biol Psychiatry 2008
364
14

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Donald C Goff, Lawrence Herz, Thomas Posever, Vivian Shih, Guochuan Tsai, David C Henderson, Oliver Freudenreich, A Eden Evins, Iftah Yovel, Hui Zhang,[...]. Psychopharmacology (Berl) 2005
86
15

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Jonathan Shimoni, Baruch Shapira, Gail Silipo, Daniel C Javitt. Am J Psychiatry 2002
146
13

Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.
Deepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, Savita Bhakta, Nagendra M Singh, Richa Yadav, Danielle Abi-Saab, Brian Pittman, Santosh K Chaturvedi, Mahendra P Sharma,[...]. Neuropsychopharmacology 2013
50
26

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Chun-Yuan Lin, Sun-Yuan Liang, Yue-Cune Chang, Shuo-Yen Ting, Ching-Ling Kao, Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane. World J Biol Psychiatry 2017
50
26


D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor.
J P Mothet, A T Parent, H Wolosker, R O Brady, D J Linden, C D Ferris, M A Rogawski, S H Snyder. Proc Natl Acad Sci U S A 2000
851
12

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.
L Verrall, P W J Burnet, J F Betts, P J Harrison. Mol Psychiatry 2010
117
12



D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Joshua T Kantrowitz, Scott W Woods, Eva Petkova, Barbara Cornblatt, Cheryl M Corcoran, Huaihou Chen, Gail Silipo, Daniel C Javitt. Lancet Psychiatry 2015
91
13

Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia.
Caroline Madeira, Maria Eliza Freitas, Charles Vargas-Lopes, Herman Wolosker, Rogério Panizzutti. Schizophr Res 2008
144
11

D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.
Toshiharu Shimazaki, Ayaka Kaku, Shigeyuki Chaki. Psychopharmacology (Berl) 2010
67
16

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia.
Louise Verrall, Mary Walker, Nancy Rawlings, Isabel Benzel, James N C Kew, Paul J Harrison, Philip W J Burnet. Eur J Neurosci 2007
138
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.